(Q24244161)

ORCID Public Data File 2021

author name string

Kwok Keung Yuen

0 references

Mike Shelley

0 references

Wai Man Sze

0 references

Malcolm Mason

Cochrane Database of Systematic Reviews

0 references

publication date

18 October 2006

0 references

published in

0 references

cites work

Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Evaluation of the effect of oral clodronate on skeletal metastases with type 1 collagen metabolites. A controlled trial of the finnish prostate cancer group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Concomitant i.v. and oral clodronate in the relief of bone pain – a double-blind placebo-controlled study in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Treatment of painful prostatic bone metastases with oral etidronate disodium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Skeletal response to clodronate in prostate cancer with bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Ibandronate in the treatment of prostate cancer associated painful osseous metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

CONSORT statement: extension to cluster randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Treatment of bone diseases with bisphosphonates, excluding osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Development of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Prostate cancer diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

State-of-the-art treatment of metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

What is meant by intention to treat analysis? Survey of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Guides for reading and interpreting systematic reviews: III. How did the authors synthesize the data and make their conclusions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Clinical approaches to osseous metastases in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Bisphosphonates for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Bisphosphonates: new indications and methods of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Role of bisphosphonates in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

The antineoplastic role of bisphosphonates: from basic research to clinical evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Systematic review of bisphosphonates for hypercalcaemia of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Core outcome domains for chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

Guides for reading and interpreting systematic reviews: II. How did the authors find the studies and assess their quality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

inferred from DOI database lookup

7 January 2021

based on heuristic

Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250

inferred from DOI database lookup

7 January 2021

based on heuristic

Biphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006250